Many people hope that a simple genetic test could tell them which antidepressant will work best for them. This hope drives a lot of anxiety and money spent on tests that may not help. A new review looked at data from 599 Caucasian patients who were dealing with a major depressive episode. These patients took common medications like SSRIs, SNRIs, or TCAs to try to feel better again. The researchers wanted to see if certain genetic variations linked to brain growth could predict who would get better.
The study checked for a specific genetic pattern called BDNF Val66Met. This pattern is found in people who carry a Met allele versus those who do not. The main goal was to see if having one version of the gene made remission more likely. Remission means the patient reached a level of symptom relief where they felt significantly better. The results showed no significant difference between the groups.
Patients with the genetic pattern that was thought to be better had a remission rate of 56.4%. Those with the other pattern had a remission rate of 54.3%. The numbers were very close and the difference was not statistically significant. This means the genetic test did not help predict who would recover. The review did not report any safety issues or side effects for the medications used in these studies.
This finding is important because it suggests we should not rely on these specific genetic markers to choose a treatment. The review notes that the evidence is limited to this specific group of patients and these specific genes. While it is good news that the drugs worked for most people regardless of the gene, it is a reality check for those hoping for a perfect genetic match. We must accept that finding the right treatment often takes time and trial rather than a simple genetic answer.
